Peptide Schedule

Sermorelin

Growth HormoneInjectionFDA ApprovedGrade B~10-20 min half-life
GHRH AnalogGrowth HormoneGH SecretagogueAnti-AgingSleep Optimization

Benefits

Decades of clinical safety data
Stimulates natural pulsatile GH release
FDA-approved (for diagnostic use)
Improves sleep quality
Well-suited for long-term use
Half-Life
~10-20 min
Route
Injection
Frequency
Daily
Vial Sizes
5mg
BAC Water
2mL
Safety Grade
Grade B
Open Sermorelin Dosage Calculator
Calculate exact syringe units for your vial and dose

About Sermorelin

Sermorelin is the original growth hormone releasing hormone (GHRH) analog with the longest clinical track record of any GH peptide. It contains the first 29 amino acids of natural GHRH — the biologically active portion. FDA-approved for diagnosing GH deficiency, it stimulates natural, pulsatile GH release from the pituitary. It's the most conservative choice for GH optimization.

Who Should Consider Sermorelin

  • Adults over 30 experiencing age-related GH decline (somatopause)
  • Patients undergoing GH deficiency diagnostic testing
  • Individuals seeking conservative, well-studied GH optimization
  • Adults with poor sleep quality seeking improved deep sleep phases
  • Clinicians preferring a peptide with decades of clinical safety data

What to Expect

Week 1-2

Improved sleep depth and quality often noticed first. Mild facial flushing may occur around injection time. GH pulses begin to normalize.

Weeks 3-4

Recovery between workouts improves. Energy and mood stabilize. Skin hydration begins to improve as IGF-1 levels rise.

Months 2-3

Body composition shifts become measurable — modest fat loss, improved muscle tone. Hair and nail growth may accelerate. Joint comfort improves.

Months 4-6

Peak benefits for body composition, sleep, and recovery. IGF-1 levels plateau at new baseline. Skin thickness may increase based on clinical data.

Month 6+

Benefits are sustained with continued use. Periodic IGF-1 monitoring recommended. Some practitioners cycle 5 days on, 2 days off to maintain pituitary sensitivity.

Dosing Protocol

LevelDose / InjectionFrequency
Beginner200mcgDaily
Moderate300mcgDaily
Aggressive500mcgDaily

Note: Original GH-releasing peptide with decades of clinical data. FDA-approved for GH deficiency diagnosis. Best dosed before bed on empty stomach. Conservative and well-studied.

Pharmacokinetics

Half-Life
11min
Bioavailability
SC: ~6%
Tmax
5-20 minutes (plasma); GH peak at ~30-60 minutes
Data Confidence
high

Source: Geref product label and PK studies; IV t½ ~6-7 min, SC t½ ~11-12 min (reported as 10-20 min range)

Pharmacokinetics — Active Dose Over Time

t½ = ~10-20 min
50%25%12.5%100%75%50%25%0%015m30m45m1h1hTime after injectionDose remaining
After 1 half-life (15m): 50% remainsAfter 2 half-lives (30m): 25% remainsAfter 3 half-lives (45m): 12.5% remains
At a 300mcg dose: 50% = 150mcg remaining after 15m. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Side Effects

Facial flushing, headache, dizziness, injection site reactions. Generally very well-tolerated.

Contraindications

  • Active cancer or history of malignancy — GH promotes cell proliferation and tumor growth
  • Pregnancy or breastfeeding — effects on fetal development have not been established
  • Active pituitary tumors or intracranial neoplasms
  • Known hypersensitivity to sermorelin acetate or any excipients
  • Untreated hypothyroidism — may impair GH response to sermorelin

Drug Interactions

  • Glucocorticoids (prednisone, dexamethasone) — chronic use may blunt GH response and reduce sermorelin efficacy
  • Insulin and oral hypoglycemics — GH release antagonizes insulin action; glucose monitoring required
  • Somatostatin analogs (octreotide, lanreotide) — directly inhibit GH release, counteracting sermorelin effects
  • Cyclooxygenase inhibitors (aspirin, indomethacin) — may alter GH response to sermorelin
  • Thyroid hormones — GH can accelerate T4-to-T3 conversion; monitor thyroid function during concurrent use
  • Muscarinic antagonists (atropine) — may modify the GH-releasing response

Molecular Profile

Amino Acids
29
Molecular Weight
3,357.93 Da
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR
HydrophobicPolarPositiveNegativeSpecial

Related Peptides

CJC-1295 (No DAC)
Growth Hormone
Ipamorelin
Growth Hormone
Tesamorelin
Growth Hormone

References

  1. Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency?PubMed 18046908
  2. Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone DeficiencyPubMed 18031173
  3. Once Daily Subcutaneous GHRH Therapy Accelerates Growth in GH-Deficient Children During the First Year of Therapy (Geref International Study Group)PubMed 8772599
  4. Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]GHRH-(1-29)-NH2 in Age-Advanced Men and WomenPubMed 9141536
  5. Geref (sermorelin acetate for injection) FDA Prescribing InformationFDA Label

Frequently Asked Questions